Rhenman & Partners Asset Management AB trimmed its holdings in shares of Edwards Lifesciences Corp (NYSE:EW) by 60.1% in the first quarter, Holdings Channel reports. The institutional investor owned 26,585 shares of the medical research company’s stock after selling 40,000 shares during the period. Rhenman & Partners Asset Management AB’s holdings in Edwards Lifesciences were worth $5,087,000 as of its most recent SEC filing.

Other institutional investors have also bought and sold shares of the company. BlackRock Inc. raised its holdings in Edwards Lifesciences by 7.4% in the 4th quarter. BlackRock Inc. now owns 16,431,419 shares of the medical research company’s stock valued at $2,516,802,000 after acquiring an additional 1,128,082 shares during the period. Oregon Public Employees Retirement Fund raised its holdings in Edwards Lifesciences by 21,360.5% in the 4th quarter. Oregon Public Employees Retirement Fund now owns 10,636,891 shares of the medical research company’s stock valued at $69,000 after acquiring an additional 10,587,326 shares during the period. FMR LLC raised its holdings in Edwards Lifesciences by 28.9% in the 4th quarter. FMR LLC now owns 7,576,820 shares of the medical research company’s stock valued at $1,160,540,000 after acquiring an additional 1,700,199 shares during the period. Jennison Associates LLC raised its holdings in Edwards Lifesciences by 184.7% in the 4th quarter. Jennison Associates LLC now owns 4,112,133 shares of the medical research company’s stock valued at $629,855,000 after acquiring an additional 2,667,749 shares during the period. Finally, Norges Bank bought a new position in Edwards Lifesciences in the 4th quarter valued at about $559,646,000. Institutional investors own 84.87% of the company’s stock.

A number of brokerages have issued reports on EW. Credit Suisse Group began coverage on shares of Edwards Lifesciences in a research report on Monday, December 17th. They set an “outperform” rating and a $188.00 target price on the stock. Citigroup increased their target price on shares of Edwards Lifesciences from $118.00 to $119.00 and gave the stock a “sell” rating in a research report on Wednesday, January 2nd. Deutsche Bank began coverage on shares of Edwards Lifesciences in a research report on Wednesday, January 2nd. They set a “hold” rating and a $164.00 target price on the stock. Canaccord Genuity increased their target price on shares of Edwards Lifesciences from $177.00 to $186.00 and gave the stock a “positive” rating in a research report on Wednesday, January 16th. Finally, Bank of America upgraded shares of Edwards Lifesciences from a “neutral” rating to a “buy” rating and increased their target price for the stock from $180.00 to $190.00 in a research report on Friday, January 18th. Two analysts have rated the stock with a sell rating, seven have assigned a hold rating and thirteen have issued a buy rating to the company. The stock currently has an average rating of “Buy” and a consensus price target of $180.71.

In other Edwards Lifesciences news, VP Larry L. Wood sold 6,716 shares of the firm’s stock in a transaction that occurred on Monday, February 4th. The shares were sold at an average price of $169.10, for a total value of $1,135,675.60. Following the sale, the vice president now owns 35,224 shares in the company, valued at $5,956,378.40. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through this link. Also, VP Catherine M. Szyman sold 700 shares of the firm’s stock in a transaction on Tuesday, January 15th. The shares were sold at an average price of $155.00, for a total transaction of $108,500.00. Following the transaction, the vice president now directly owns 24,482 shares of the company’s stock, valued at approximately $3,794,710. The disclosure for this sale can be found here. Insiders sold 113,554 shares of company stock worth $19,946,796 in the last 90 days. Company insiders own 1.84% of the company’s stock.

NYSE EW opened at $188.83 on Thursday. The company has a current ratio of 2.61, a quick ratio of 1.92 and a debt-to-equity ratio of 0.19. The company has a market cap of $39.52 billion, a P/E ratio of 40.18, a PEG ratio of 2.45 and a beta of 0.91. Edwards Lifesciences Corp has a 1 year low of $123.00 and a 1 year high of $197.86.

Edwards Lifesciences (NYSE:EW) last posted its quarterly earnings results on Thursday, January 31st. The medical research company reported $1.17 earnings per share (EPS) for the quarter, hitting the Thomson Reuters’ consensus estimate of $1.17. Edwards Lifesciences had a net margin of 19.40% and a return on equity of 31.09%. The business had revenue of $977.70 million for the quarter, compared to analyst estimates of $973.72 million. During the same quarter last year, the business posted $0.94 EPS. Equities analysts expect that Edwards Lifesciences Corp will post 5.21 EPS for the current year.

TRADEMARK VIOLATION WARNING: “Rhenman & Partners Asset Management AB Sells 40,000 Shares of Edwards Lifesciences Corp (EW)” was originally reported by Watch List News and is the property of of Watch List News. If you are reading this story on another site, it was copied illegally and republished in violation of U.S. & international copyright & trademark laws. The correct version of this story can be viewed at https://www.watchlistnews.com/rhenman-partners-asset-management-ab-sells-40000-shares-of-edwards-lifesciences-corp-ew/2954999.html.

About Edwards Lifesciences

Edwards Lifesciences Corporation provides products and technologies for structural heart disease and critical care monitoring in the United States and internationally. It offers transcatheter heart valve therapy products comprising transcatheter aortic valve replacement, and transcatheter mitral and tricuspid therapies for the nonsurgical replacement of heart valves.

Further Reading: What are gap-up stocks?

Want to see what other hedge funds are holding EW? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Edwards Lifesciences Corp (NYSE:EW).

Institutional Ownership by Quarter for Edwards Lifesciences (NYSE:EW)

Receive News & Ratings for Edwards Lifesciences Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Edwards Lifesciences and related companies with MarketBeat.com's FREE daily email newsletter.